ArticleActa orthopaedica2025
Incidence of and survival after surgery for metastatic spine disease: a nationwide register-based study between 1997 and 2020 from Finland.
Article in Acta orthopaedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends and postoperative complications of spinal metastasis surgery in Thailand between 2015 and 2024: a nationwide retrospective cohort study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeInformation on metastatic spine disease (MSD) based on nationwide data on trends and postoperative survival is limited but is needed to optimize treatment in this population. We aimed to assess the incidence of and survival rates after MSD surgery.
methodsThis retrospective nationwide register-based study combined data from the Finnish Cancer Registry, Finnish Care Register for Health Care, and the Finnish Cause of Death Register from 1997 to 2020. Surgeries were identified using diagnosis and procedural codes, with primary spine pathologies excluded. Incidence rates were calculated per 100,000 inhabitants and adjusted for age and sex. Survival analysis was conducted using the Kaplan-Meier estimator.
results1,845 patients underwent 1,992 surgeries, with a mean age of 65 years; 58% were men. The most common primary cancers were prostate cancer (15.1%), breast cancer (11.6%), and myeloma (10.6%). The incidence of MSD surgery increased by 87%, from 1.05 to 1.97 per 100,000 person-years. Surgery increased most among patients aged 70-79 years. Over the same period, the 6-month survival remained fairly stable. The overall survival probabilities were 57% (95% confidence interval [CI] 54-59) at 1 year, 44% (CI 42-46) at 2 years, 28% (CI 26-30) at 5 years, and 18% (CI 16-20) at 10 years. The 1-year survival was highest in patients with breast cancer at 75% (CI 69-81) and lowest in patients with kidney cancer at 45% (CI 38-53) and prostate cancer at 47% (CI 42-53).
conclusionFinnish nationwide data showed an increase in MSD surgery between 1997 and 2020 with a stable postoperative survival of 57% (CI 48-69) to 76% (CI 66-89) at 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.